Drug Trial Radar · NCT01411228
A Multicenter Extension Study of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease
Last checked: Nov 20, 2026Latest source record: Sep 7, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
15
Actual
Start
Sep 2011
Primary completion
Jul 2014
Study completion Aug 2014
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Aug 8, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 2 years, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A protocol to extend the assessment of the safety and efficacy of taliglucerase alfa in pediatric subjects (2 to \<18 years old) with symptoms and clinical manifestations of Gaucher disease who completed treatment in Protocols PB-06-002 (switchover study from imiglucerase) or PB-06-005 (naïve treatment with taliglucerase alfa).
Conditions
- Gaucher Disease
Interventions
Taliglucerase alfaDrug
Taliglucerase alfa for infusion every two weeks for 24 months
Primary outcomes
What the sponsor says the trial is designed to measure.
- HemoglobinTime frame: Baseline, months 9, 12 and 24
Locations
3 sites in 3 countries. Site status is shown where the registry gives one.
Shaare Zedek Medical Center
Jerusalem, Israel
Instituto Privado de Hematologia E Investigacion Clinica (I.P.H.I.C)
Barrio Asunción, Paraguay
Morningside Medi-Clinic
Morningside, South Africa
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.